Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Clinical Study to Evaluate the Safety, Tolerance, Efficacy and Pharmacokinetics of TFX06 Tablet in ER Positive, HER Negative Locally Advanced or Metastatic Breast Cancer.

NCT05927779 is registered in ClinicalTrials.gov with Zhejiang Yangli Pharmaceutical Technology Co., Ltd. as lead sponsor.

NCT NCT05927779
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05927779 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Clinical Study to Evaluate the Safety, Tolerance, Efficacy and Pharmacokinetics of TFX06 Tablet in ER Positive, HER Negative Locally Advanced or Metastatic Breast Cancer.
Lead sponsor
Zhejiang Yangli Pharmaceutical Technology Co., Ltd.
Phase
Phase 1/2
Overall status
Unknown status
Start date
April 17, 2023
Completion date
April 30, 2025
Enrollment
74 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

er+, her2- advanced breast cancer, metastatic breast cancer